IMGN ImmunoGen Inc

ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that its presentation at the J.P. Morgan 30th Annual Healthcare Conference at 2:00 pm PT on January 10, 2012 will be webcast live.

The webcast of this presentation can be accessed live through the "Investor Information" section of the Company's website, www.immunogen.com; a replay of the presentation will be available at the same location for two weeks.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies, potent cancer-cell killing agents and engineered linkers. The Company's Targeted Antibody Payload (TAP) technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents specifically to tumor cells. There are now numerous TAP compounds in clinical development with a wealth of clinical data reported. ImmunoGen's collaborative partners include Amgen, Bayer HealthCare Pharmaceuticals, Biotest, Lilly, Novartis, Roche, and Sanofi. The most advanced compound using ImmunoGen's TAP technology, trastuzumab emtansine (T-DM1), is in Phase III testing through the Company's collaboration with Genentech, a member of the Roche Group. More information about ImmunoGen can be found at www.immunogen.com.

CONTACT: For Investors:
         Carol Hausner
         Executive Director, Investor Relations and
         Corporate Communications
         ImmunoGen, Inc.
         (781) 895-0600
         info@immunogen.com
         
         For Media:
         Barbara Yates
         The Yates Network
         (781) 258-6153